The Technical Analyst
Rallybio Corporation [RLYB]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Rallybio Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.39% $1.760
/ 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 66.55 mill |
| EPS: | -1.840 |
| P/E: | -0.960 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 37.81 mill |
| Avg Daily Volume: | 1.614 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.960 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.960 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.596 (-66.14%) $-1.164 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.564 - 1.956 ( +/- 11.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-15 | Uden Stephen | Buy | 216 000 | Option (Right to Buy) |
| 2024-02-15 | Mackay Martin | Buy | 216 000 | Option (Right to Buy) |
| 2024-02-15 | Lieber Jonathan I | Buy | 120 000 | Option (Right to Buy) |
| 2024-02-15 | Ryder Steven | Buy | 120 000 | Option (Right to Buy) |
| 2024-01-02 | Parmar Kush | Buy | 27 118 | Option (Right to Buy) |
| INSIDER POWER |
|---|
| 88.14 |
| Last 96 transactions |
| Buy: 12 129 861 | Sell: 21 341 220 |
Forecast:
16:00 - $1.740
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.740
Forecast 2: 16:00 - $1.740
Forecast 3: 16:00 - $1.740
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.760 (5.39% ) |
| Volume | 0.313 mill |
| Avg. Vol. | 1.614 mill |
| % of Avg. Vol | 19.40 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RLYB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Latest Press Releases
2024-04-17 16:01:00 - Press Release
Fnait Systematic Literature Review And Meta-analysis Presented At The Academy Of Managed Care Pharmacy 2024 Annual Meeting
New haven, conn.--(business wire)--rallybio corporation (nasdaq: rlyb), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a fetal and neonatal alloimmune thrombocytopenia (fnait) systematic literature review and meta-analysis at the academy of managed care pharmacy (amcp) 2024 annual meeting, which is taking place in new orlea.
2024-04-10 16:01:00 - Press Release
Rallybio Announces Collaboration To Advance Therapeutic Solutions For Pregnant Individuals At Risk Of Fetal And Neonatal Alloimmune Thrombocytopenia (fnait)
New haven, conn.--(business wire)--rallybio corporation (nasdaq: rlyb), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with johnson & johnson1 to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (fnait). in addition, rallybio received an equity i.
2024-03-12 08:00:00 - Press Release
Rallybio Reports Fourth Quarter And Full Year 2023 Financial Results
New haven, conn.--(business wire)--rallybio corporation (nasdaq: rlyb), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth quarter and full year ended december 31, 2023 and provided an update on recent program and corporate developments. “we are encouraged by the continued progress we made across our portfolio throughout 2023. f.
2024-02-26 08:00:00 - Press Release
Rallybio To Present At The Td Cowen 44th Annual Health Care Conference
New haven, conn.--(business wire)--rallybio corporation (nasdaq: rlyb), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that steve uden, m.d., chief executive officer of rallybio, will participate in a panel discussion, “orphan bone & neuromuscular diseases,” at the td cowen 44th annual health care conference on monday, march 4, 2024 at 9:10 a.m. est in.
2024-01-04 08:00:00 - Press Release
Rallybio Highlights Portfolio Advances And Outlines Expected Milestones In 2024
New haven, conn.--(business wire)--rallybio corporation (nasdaq: rlyb), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected 2024 milestones. the company will present these updates at the 42nd annual j.p. morgan health care conference in san francisco, california on wednesday, january 10, 2024, at 8:15 a.
Latest News
2024-04-12 11:26:03 - Zacks Investment Research
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
2024-04-11 11:32:51 - Proactive Investors
Rallybio partners with J&J to advance therapies targeting rare fetal disease
Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thrombocytopenia (FNAIT). Shares of the biotechnology company soared on the announcement, adding 69.3% at $2.76 late morning on Thursday.
2024-04-11 07:43:59 - InvestorPlace
Why Is Rallybio (RLYB) Stock Up 93% Today?
Rallybio (NASDAQ: RLYB ) stock is rocketing higher on Thursday after announcing a collaboration with Johnson & Johnson (NYSE: JNJ ). Rallybio is receiving support from Johnson & Johnson for the development of its fetal and neonatal alloimmune thrombocytopenia (FNAIT) therapies.
2023-09-15 17:15:40 - Seeking Alpha
Rallybio: Gearing Up To Be An Opportunity
Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.
2023-08-31 08:00:00 - Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 7, 2023. Stephen Uden, M.D., Chief Executive Officer, and Martin Mackay, Ph.D., Executive Chairm.
2023-06-09 09:15:00 - Business Wire
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-H.
2023-05-29 11:05:13 - Zacks Investment Research
Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade
The mean of analysts' price targets for Rallybio Corporation (RLYB) points to a 202.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-03-01 08:00:00 - Business Wire
Rallybio to Present at Upcoming Investor Conferences in March
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Cowen 43rd Annual Healthcare Conference in Boston, Massachusetts on Wednesday, March 8, 2023. Martin Mackay, Ph.D.
2022-11-29 08:00:00 - Business Wire
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022, at 1:40 p.m. ET.
2022-11-11 08:00:00 - Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
NEW HAVEN, Conn.--( BUSINESS WIRE )--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: